ALLUVI: A DEEP ANALYSIS INTO RETATRUTIDE'S POTENTIAL

Alluvi, initially dubbed LY3414901, represents a noteworthy advancement in weight management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist exhibits remarkable effectiveness in early clinical data, with substantial reduct